RenovoRx director Richard Stark reports stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RenovoRx, Inc. director Richard Stark reported directly held, fully vested and exercisable stock options on November 18, 2026. The options cover 46,000 common shares at an exercise price of $1.38 per share, expiring December 4, 2034; 12,000 shares at $1.02 per share, expiring January 5, 2036; and 50,000 shares at $0.98 per share, expiring April 2, 2036. They were granted under the issuer’s Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (right to buy) F1 | -- | -- | -- |
| Holding | Stock Option (right to buy) F1 | -- | -- | -- |
| Holding | Stock Option (right to buy) F1 | -- | -- | -- |
Footnotes (1)
- F1. The options were granted under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services provided to the Issuer and are fully vested and exercisable.
Key Figures
Key Terms
Amended and Restated 2021 Omnibus Equity Incentive Plan technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did RenovoRx director Richard Stark report?
AI-generated analysis. How Rhea-AI works. Not financial advice.